Yi Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1171598/publications.pdf

Version: 2024-02-01

		840776	1125743	
11	2,083	11	13	
papers	citations	h-index	g-index	
13	13	13	2741	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene, 2021, 40, 4992-5001.	5.9	68
2	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nature Cell Biology, 2020, 22, 1264-1275.	10.3	508
3	Isolation of cancer-derived extracellular vesicle subpopulations by a size-selective microfluidic platform. Biomicrofluidics, 2020, 14, 034113.	2.4	29
4	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Research, 2020, 80, 2298-2310.	0.9	87
5	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nature Communications, 2019, 10, 5114.	12.8	64
6	Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Research, 2019, 29, 83-86.	12.0	158
7	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Journal of Clinical Investigation, 2019, 129, 3324-3338.	8.2	209
8	Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Research, 2018, 28, 862-864.	12.0	345
9	Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. American Journal of Cancer Research, 2018, 8, 1307-1316.	1.4	42
10	In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model. Journal of Visualized Experiments, 2017, , .	0.3	4
11	Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell, 2016, 30, 925-939.	16.8	538